Evaluation of Benapryzine in Psychotic Patients Treated with Phenothiazines

Reference

• Ayd, F. J., (1961). A survey of drug-induced extrapyramidal reactions. J. Amer. med. Ass., 175, 1054–1060.1. Ayd, F. J., (1961). A survey of drug-induced extrapyramidal reactions. J. Amer. med. Ass., 175, 1054–1060.
   PubMed Web of Science ®Google Scholar
• Brown, D. M., Hughes, B. O., Marsden, C. D., Meadows, J. C., and Spicer, B., (1973). Some initial animal and human pharmacological studies with benapryzine (BRL 1288). Brit. J. Pharmacol., 47, 476.2. Brown, D. M., Hughes, B. O., Marsden, C. D., Meadows, J. C., and Spicer, B., (1973). Some initial animal and human pharmacological studies with benapryzine (BRL 1288). Brit. J. Pharmacol., 47, 476.
   PubMed Web of Science ®Google Scholar
• Brown, D. M., Hughes, B. O., and Mehta, M. D., (1969). BRL 1288 - a new anti-Parkinson drug. Nature, 223, 416.3. Brown, D. M., Hughes, B. O., and Mehta, M. D., (1969). BRL 1288 - a new anti-Parkinson drug. Nature, 223, 416.
   PubMed Web of Science ®Google Scholar
• Clarke, G., and Davies, J., (1973). The effects of anti-Parkinson drugs on cortical neurones. Brit. J. Pharmacol., 47, 465–475.4. Clarke, G., and Davies, J., (1973). The effects of anti-Parkinson drugs on cortical neurones. Brit. J. Pharmacol., 47, 465–475.
   PubMed Web of Science ®Google Scholar
• Crawford, R., and Forrest, A., (1974). Controlled trial of depot fluphenazine in out-patient schizophrenics. Brit. J. Psychiat., 124, 385–391.5. Crawford, R., and Forrest, A., (1974). Controlled trial of depot fluphenazine in out-patient schizophrenics. Brit. J. Psychiat., 124, 385–391.
   PubMed Web of Science ®Google Scholar
• Davies, J. A., Jackson, B., and Redfern, P. H., (1973). The effect of anti-Parkinsonian drugs on haloperidol induced inhibition of the conditioned-avoidance response in rats. Neuropharmacology, 12, 735.6. Davies, J. A., Jackson, B., and Redfern, P. H., (1973). The effect of anti-Parkinsonian drugs on haloperidol induced inhibition of the conditioned-avoidance response in rats. Neuropharmacology, 12, 735.
   PubMed Web of Science ®Google Scholar
• Denham, J., (1961). The implications of extrapyramidal symptoms in the treatment of schizophrenia. Rev. canad. Biol., 20, 545–548.7. Denham, J., (1961). The implications of extrapyramidal symptoms in the treatment of schizophrenia. Rev. canad. Biol., 20, 545–548.
   PubMedGoogle Scholar
• Hornykiewicz, D., (1966). Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev., 18, 952–964.8. Hornykiewicz, D., (1966). Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev., 18, 952–964.
   Google Scholar
• Hunter, K. R., and Robinson, O. P. W., (1972). Anticholinergic drugs in Parkinsonism - a controlled trial of benapryzine (Brizin). Clin. Trials J., 9, 3.9. Hunter, K. R., and Robinson, O. P. W., (1972). Anticholinergic drugs in Parkinsonism - a controlled trial of benapryzine (Brizin). Clin. Trials J., 9, 3.
   Google Scholar
• Jeffery, D. J., Brown, D. M., and Langley, P. F., (1971). The metabolism and distribution of benapryzine. Xenobiotica, 1, 169.10. Jeffery, D. J., Brown, D. M., and Langley, P. F., (1971). The metabolism and distribution of benapryzine. Xenobiotica, 1, 169.
   PubMedGoogle Scholar
• Johnson, D. A. W., (1973). The side-effects of fluphenazine decanoate. Brit. J. Psychiat., 123, 519.11. Johnson, D. A. W., (1973). The side-effects of fluphenazine decanoate. Brit. J. Psychiat., 123, 519.
   PubMed Web of Science ®Google Scholar
• Millar, J., and Daniel, G. R., (1967). A trial of fluphenazine enanthate in chronic schizophrenia. Brit. J. Psychiat., 113, 1431.12. Millar, J., and Daniel, G. R., (1967). A trial of fluphenazine enanthate in chronic schizophrenia. Brit. J. Psychiat., 113, 1431.
   PubMed Web of Science ®Google Scholar
• Neal, C. D., and Imlah, N. W., (1968). Fluphenazine decanoate: a second long-acting phenothiazine. Brit. J. soc. Psychiat., 2, 178.13. Neal, C. D., and Imlah, N. W., (1968). Fluphenazine decanoate: a second long-acting phenothiazine. Brit. J. soc. Psychiat., 2, 178.
   Google Scholar
• Pletscher, A., and Da Prada, M., (1966). Mechanism of action of neuroleptics.. Proc. V Int. Congress Coll. Int. Neuro-psycho-pharmacology.. p.304. Excerpta Medica, Washington, D.C.14. Pletscher, A., and Da Prada, M., (1966). Mechanism of action of neuroleptics. Proc. V Int. Congress Coll. Int. Neuro-psycho-pharmacology. p.304. Excerpta Medica, Washington, D.C.
   Google Scholar
• Shepherd, M., Lader, M., and Rodnight, R., (1968). “Clinical Psychopharmacology”. English Universities Press, London.15. Shepherd, M., Lader, M., and Rodnight, R., (1968). “Clinical Psychopharmacology”. English Universities Press, London.
   Google Scholar
• Shore, P. A., (1962). Release of serotonin and catecholamine by drugs. Pharmacol. Rev., 14, 531.16. Shore, P. A., (1962). Release of serotonin and catecholamine by drugs. Pharmacol. Rev., 14, 531.
   PubMed Web of Science ®Google Scholar
• Vicary, D. J., Horrocks, P. M., Rees, J. E., Parkes, J. D., and Marsden, C. D., (1973). The treatment of patients with Parkinson's Disease receiving levodopa. A comparison of benapryzine (Brizin) and benzhexol. Clin. Trials J., 10, 3.17. Vicary, D. J., Horrocks, P. M., Rees, J. E., Parkes, J. D., and Marsden, C. D., (1973). The treatment of patients with Parkinson's Disease receiving levodopa. A comparison of benapryzine (Brizin) and benzhexol. Clin. Trials J., 10, 3.
   Google Scholar